In a landmark year for the life sciences and pharmaceutical industries, 2025 marked a definitive pivot towards the widespread adoption…
Read More
FDA Commissioner Marty Makary Resigns Amidst Mounting Pressure and Regulatory Turmoil
Marty Makary resigned on Tuesday as commissioner of the Food and Drug Administration, a departure precipitated by intense administrative pressure…
Read More
UniQure Secures Path to Regulatory Review for Groundbreaking Huntington’s Disease Gene Therapy After FDA Reversal
UniQure has announced a significant turning point in its pursuit of regulatory approval for AMT-130, a pioneering gene therapy aimed…
Read More
AI Transforms Pharmaceutical Regulatory Submissions: Predictive Intelligence and End-to-End Pipelines Emerge as Game-Changers
The pharmaceutical industry is undergoing a profound transformation driven by the rapid integration of Artificial Intelligence (AI), moving beyond early-stage…
Read More
The $1.8 Billion Telehealth Conundrum: Medvi’s Rise Amidst Regulatory Gaps, AI Deception, and the Compounded Drug Market
A recent profile by The New York Times celebrated Medvi, a burgeoning telehealth enterprise, as a testament to the transformative…
Read More
Medvi: The $1.8 Billion Telehealth Company Built on Regulatory Gaps, Fake Testimonials, and AI Deception
A recent profile by The New York Times lauded Medvi as a prime example of artificial intelligence’s potential to empower…
Read More
Medvi’s QUAD Erectile Dysfunction Cocktail Raises Significant Safety Concerns Amidst Regulatory Scrutiny and Questionable Marketing Practices
The burgeoning telehealth industry, lauded for its potential to democratize healthcare access, is facing intensified scrutiny as companies push the…
Read More
How Medvi Built a $1.8 Billion Telehealth Empire in Regulatory Blind Spots: A Deep Dive into AI, Compounding, and Fragmented Oversight
The rapid ascent of Medvi, a telehealth company projected to achieve a staggering $1.8 billion valuation this year, has thrust…
Read More
Novartis Secures Dual Regulatory Milestones: European Approval for Rhapsido and WHO Prequalification for Coartem Baby
Novartis has achieved significant regulatory successes on two fronts, with its oral therapy Rhapsido (remibrutinib) receiving marketing authorisation from the…
Read More
Regulatory round-up: Novartis, Sanofi and Arrowhead secure CHMP blessings – Pharmaceutical Technology
The European Committee for Medicinal Products for Human Use (CHMP) has issued positive opinions on three promising new drug candidates,…
Read More
